Key result
Trial randomization error analysis identifies 17 causes driven by lacking institutional procedural infrastructure.
Why the study?
Participants in an NIH-funded multicenter clinical trial received the compound opposite to the randomization intention, prompting a Root Cause Analysis and Corrective And Preventative Action.
Case Report (n=28)
Double-blind
Randomized
Yes
Institutional processes and controls are critical to ensure study teams appropriately identify and manage critical-to-quality factors to prevent severe clinical trial errors such as randomization mismatches.
Answers are grounded in this paper and cite their sources.
May prompt local trial-site procedural reviews; leaves open whether RCA-driven fixes reduce errors across trials.
Introduction: Participants in NIH-funded multicenter clinical trial received the compound opposite to the randomization intention. We report the problem, subsequent root cause analysis (RCA) and corrective and preventative action (CAPA). Methods: The RCA was independently facilitated to identify study-level causes of the problem. Results were reviewed by institutional research administration leaders to identify institution-level causes and formulate corresponding CAPA. Both culminated in consensus. Results: The resulting causal chain consisted of two physical causes, two study-level system causes, and two institution-level system causes for which two institution-level CAPAs were formulated by institutional leadership. The CAPAs established institutional procedures for independent verification of critical processes, their specification, and their planned control on high-risk studies. Conclusions: Lack of study-level procedural infrastructure jeopardized a multicenter study led by our institution. Lack of institutional infrastructure supporting identification of critical study processes, risks to them, and appropriate controls enabled the problem to occur. Studies conducted in settings lacking institutional or study-level procedural infrastructure are susceptible to similar problems. Adding the needed institutional processes to support identification of critical study processes, risks to them, and appropriate controls required reprioritizing existing resources.
No takes yet. Share an insight, caveat, or question.
Hamidi et al. (2026) conducted a case report in COVID-19 infection and acute kidney injury (n=28). Nicotinamide riboside vs. Placebo was evaluated on Whole blood nicotinamide adenine dinucleotide (NAD+) levels. Root cause analysis of a clinical trial randomization error identified 17 causes, primarily a lack of study-level and institutional procedural infrastructure, leading to new institutional verification procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: